Reversing cachexia

Michael J. Tisdale

Research output: Contribution to journalArticle

Abstract

Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

LanguageEnglish
Pages511-512
Number of pages2
JournalCell
Volume142
Issue number4
DOIs
Publication statusPublished - 20 Aug 2010

Fingerprint

Cachexia
Muscle
Activins
Activin Receptors
Muscular Atrophy
Myocardium
Skeletal Muscle
Neoplasms
Therapeutics

Cite this

Tisdale, M. J. (2010). Reversing cachexia. Cell, 142(4), 511-512. https://doi.org/10.1016/j.cell.2010.08.004
Tisdale, Michael J. / Reversing cachexia. In: Cell. 2010 ; Vol. 142, No. 4. pp. 511-512.
@article{02e67cc7dbd34a33b215a9d6f4d00249,
title = "Reversing cachexia",
abstract = "Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.",
author = "Tisdale, {Michael J.}",
year = "2010",
month = "8",
day = "20",
doi = "10.1016/j.cell.2010.08.004",
language = "English",
volume = "142",
pages = "511--512",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "4",

}

Tisdale, MJ 2010, 'Reversing cachexia' Cell, vol. 142, no. 4, pp. 511-512. https://doi.org/10.1016/j.cell.2010.08.004

Reversing cachexia. / Tisdale, Michael J.

In: Cell, Vol. 142, No. 4, 20.08.2010, p. 511-512.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reversing cachexia

AU - Tisdale, Michael J.

PY - 2010/8/20

Y1 - 2010/8/20

N2 - Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

AB - Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

UR - http://www.scopus.com/inward/record.url?scp=77955702860&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2010.08.004

DO - 10.1016/j.cell.2010.08.004

M3 - Article

VL - 142

SP - 511

EP - 512

JO - Cell

T2 - Cell

JF - Cell

SN - 0092-8674

IS - 4

ER -

Tisdale MJ. Reversing cachexia. Cell. 2010 Aug 20;142(4):511-512. https://doi.org/10.1016/j.cell.2010.08.004